Loading organizations...
§ Private Profile · Bengaluru, Karnataka, India
AI platform for antibody discovery and screening, for biotech and pharma, targeting cancer and autoimmune disorders.
immunitoAI, based in Bengaluru, India, develops an AI-powered platform for antibody discovery and screening. The company's technology, featuring tools like imDESIGN and imRANK, generates novel antibodies from scratch and evaluates candidates for optimal binding to targets. This approach aims to significantly reduce discovery time from 4-5 years to 11-12 months and cut associated costs by up to 50%, while improving success rates for therapeutics targeting diseases such as cancer and autoimmune disorders. immunitoAI secured $1 million in seed funding in September 2021, with pi Ventures leading the round. Earlier, Entrepreneur First provided pre-seed capital, originating from their talent program. The organization was founded in 2020 by Aridni Shah, who serves as CEO, and Trisha Chatterjee, the CTO. Its business model centers on provides AI services to pharmaceutical companies for antibody discovery, funded through seed investments used for product development and partnerships.
immunitoAI has raised $7.1M across 2 funding rounds.
immunitoAI has raised $7.1M in total across 2 funding rounds.
immunitoAI has raised $7.1M in total across 2 funding rounds.
immunitoAI's investors include Ashish Kacholia, 3one4 Capital, AC Ventures, Anicut Capital, JITO Angel Network, JJ Family Office, Roopan Aulakh, Entrepreneur First.
immunitoAI has raised $7.1M across 2 funding rounds. Most recently, it raised $6.1M Series A in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 26, 2025 | $6.1M Series A | Ashish Kacholia | 3one4 Capital, AC Ventures, Anicut Capital, Jito Angel Network, JJ Family Office, Roopan Aulakh | Announced |
| Sep 9, 2021 | $1M Seed | Roopan Aulakh | Entrepreneur First | Announced |